Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Change in Accured Expenses data on file, last reported at $8.4 million in Q2 2026.

• Quarterly Change in Accured Expenses fell 42.5% year-over-year to $8.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$642000.0 (up 55.82% YoY) and the FY2025 annual result came in at -$1.4 million, down 137.95% from the prior year.
• Change in Accured Expenses advanced to $8.4 million in Q2 2026, from -$19.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $14.5 million in Q2 2025 to a low of -$26.1 million in Q1 2025.
• A 5-year average of $405555.6 and a median of $3.6 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1244.17% — and 2024, when it sank 364.03%.
• Tracing AGIO's Change in Accured Expenses over 5 years: stood at $5.2 million in 2022, then soared by 143.13% to $12.7 million in 2023, then gained by 6.92% to $13.6 million in 2024, then tumbled by 39.19% to $8.2 million in 2025, then gained by 1.36% to $8.4 million in 2026.
• The last three Change in Accured Expenses figures came in at $8.4 million (Q2 2026), -$19.2 million (Q1 2026), and $8.2 million (Q4 2025), per Business Quant data.